Full Press Release Details
Synta Pharmaceuticals Appoints
Donald Kufe, M.D. to Board of Directors
LEXINGTON, MA September 30,
Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a
biopharmaceutical company focused on discovering, developing, and
commercializing small molecule drugs to treat severe medical conditions, today
announced that Donald Kufe, M.D., Professor of Medicine, Dana-Farber Cancer
Institute and Harvard Medical School, has been appointed to the Board of
Directors effective September 28, 2010.
Dr. Kufe received his M.D. from the University
of Rochester School of Medicine. After a
clinical fellowship in medical oncology at Dana-Farber Cancer Institute, he
joined the staff in 1979. He has served
as chief of the Division of Cancer Pharmacology, deputy director of the
Dana-Farber/Harvard Cancer Center, director of the Harvard Phase I Oncology
Group and leader of the Experimental Therapeutics Program. He is an editor of the textbook Cancer
Medicine. Dr. Kufe is recipient of
the Richard P. and Claire W. Morse Scientific Award, DFCI, the Scholar Award,
Burroughs-Wellcome and the Faculty Research Award, American Cancer Society. Dr. Kufe currently sits on the Board of
Directors of Genus Oncology, LLC and Linus Pharmaceuticals, Inc.
With over thirty years of oncology clinical and
research experience, and as a recognized leader in translational pharmacology, Dr. Kufe
brings valuable insight and perspective to Synta. We are delighted to have him join our Board
of Directors, said Safi Bahcall, Ph.D., President and Chief Executive Officer,
Synta Pharmaceuticals.
Synta has an exciting pipeline of innovative
compounds for oncology and inflammatory diseases, with potential to provide
meaningful benefit to patients, said Dr. Kufe. I look forward to working with the Board and
management team to help realize this goal.
About Synta Pharmaceuticals
Synta Pharmaceuticals
Corp. is a biopharmaceutical company focused on discovering, developing, and
commercializing small molecule drugs to extend and enhance the lives of
patients with severe medical conditions, including cancer and chronic
inflammatory diseases. Synta has a
unique chemical compound library, an integrated discovery engine, and a diverse
pipeline of clinical- and preclinical-stage drug candidates with distinct
mechanisms of action and novel chemical structures. All Synta drug candidates were invented by
Synta scientists using our compound library and discovery capabilities. For more information, please visit
Synta Pharmaceuticals Corp.